Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation

This publication has 48 references indexed in Scilit:

• Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)
  The Lancet Oncology, 2009
• Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
  New England Journal of Medicine, 2009
• Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
  Leukemia, 2007
• Early Detection and Rapid Isolation of Leukemia-Reactive Donor T Cells for Adoptive Transfer Using the IFN-γ Secretion Assay
  Clinical Cancer Research, 2007
• Tutorial in biostatistics: competing risks and multi‐state models
  Statistics in Medicine, 2006
• T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy
  Leukemia, 2006
• Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective
  Bone Marrow Transplantation, 2004
• Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
  Leukemia, 2001
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
  The Lancet, 1998
• Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation
  European Journal of Clinical Microbiology & Infectious Diseases, 1990